The Berlin-based biotechnology company MOLOGEN AG has been informed by its license partner ONCO Life Sciences Pvt. Ltd., India, that the respective authorities have granted treatment permission for MOLOGEN’S cell-based gene therapy. This innovative cancer therapy can currently be used for the treatment of renal cell carcinoma, colon, breast, and lung cancer.
